Short Report

COVID-19 prevention with alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomide

Alex Dornburg, Ph.D.[1], Hayley B. Hassler, M.S.[2,3], Jeffrey P. Townsend, Ph.D.[2,4,5*]

[1] *Department of Bioinformatics and Genomics, University of North Carolina, Charlotte, North Carolina 28223, USA*

[2] *Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut 06510, USA*

[3] *Interdisciplinary Graduate Program in Quantitative Biosciences, Georgia Institute of Technology, Atlanta, GA 30332, USA*

[4] *Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06511, USA*

[5] *Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut 06525, USA*

[*]Corresponding Author**:** Jeffrey P. Townsend PhD, 135 College St, Suite 200 #222, New Haven, CT 06510-2483. Jeffrey.Townsend@Yale.edu, (203) 737-7042

Keywords: multiple sclerosis, disease-modifying therapy, beta-interferon, dimethyl fumarate, natalizumab

Practice Points:

1. **Tailor Booster Schedules:** Annual COVID-19 boosters are recommended for untreated MS patients and those on interferon, dimethyl fumarate, natalizumab, or teriflunomide; Bi-annual boosters would further reduce infection risk.
2. **Address Risks for Immunosuppressed Patients:** For patients on highly immunosuppressive treatments (e.g., fingolimod, ocrelizumab, rituximab), recognize diminished vaccine efficacy and consider supplemental measures for risk mitigation.
3. **Promote Booster Adherence and Education:** Encourage timely booster adherence and educate patients on the benefits of tailored vaccination schedules, while keeping in mind the potential antiviral properties of specific therapies.

Abstract

Multiple-sclerosis patients undergoing treatment with disease-modifying therapies exhibit diverse immune responses to COVID-19 vaccinations. However, guidance on how specific treatments influence infection risks and optimal vaccination schedules remains limited. This study integrates data on vaccine-induced and infection-derived antibody responses to predict cumulative probabilities of breakthrough infections in untreated multiple-sclerosis patients and those treated with interferon, dimethyl fumarate, natalizumab, or teriflunomide. Using antibody dynamics and augmented logistic regression models, we evaluated the effectiveness of different Pfizer-BioNTech BNT162b2 booster schedules.

Our findings reveal that annual boosters effectively reduce infection risks for untreated multiple-sclerosis patients, lowering their cumulative risk by more than half over two years. Among treated patients, booster vaccinations generally provide protection comparable to that of untreated patients, although treatment-specific variations in immunity are evident. For patients on interferon, annual boosters yield an even greater reduction in risk. Patients treated with dimethyl fumarate or natalizumab benefit significantly from boosters, though they experience moderately higher risks compared to untreated patients.

This study underscores the importance of tailored booster schedules for MS patients, taking into account disease-modifying-therapy-specific effects on immunity. Our analysis provides actionable insights for mitigating SARS-CoV-2 risks in this vulnerable population until broader long-term infection data are available. These findings aim to guide clinicians in optimizing care for multiple-sclerosis patients in the context of ongoing COVID-19 vaccination strategies.

Introduction

COVID-19 vaccination strategies have primarily focused on identifying optimal booster frequencies that sustain immunity within the general population [1,2]. For patients with multiple sclerosis (MS) undergoing disease-modifying therapies (DMTs), booster vaccination may be an essential tool for safe care. However, the impact of DMTs on the immune system varies significantly; some therapies appear to permit a relatively normal vaccine response, while others can severely impair the ability to respond to vaccinations [3]. Data on antibody levels following COVID-19 vaccination justify a concern that atypical responses to DMTs might entail distinct booster schedules to achieve sufficient protection [4,5]. Antibody responses are likely to vary depending on the specific DMT regimen [6,7], underscoring the need for specific guidance regarding infection risks associated with alternate frequencies of boosting [8].

Methods

Anti-S antibody levels provide an accurate correlate of protection against infection by the SARS-CoV-2 coronavirus [9], therefore we quantified risks of infection on the basis of antibody levels. We conducted a literature search for anti-S antibody levels in individuals with MS vaccinated with Pfizer-BioNTech BNT162b2. We obtained data from MS patients undergoing treatment with interferon (n = 135), dimethyl fumarate (n = 161), natalizumab (n = 74), or teriflunomide (n = 56), from a group with untreated MS (n = 205), and from a control group without MS (n = 63) [10]. Over the time points used in our analysis (4 weeks post original vaccination to 4 weeks post booster vaccination), the sampled population was 73–74% female,

48–49 years of age on average, and maintained a consistent Expanded Disability Status Scale of 2. To place antibody data into a comparative framework for analyses, we scaled antibody levels (Idda et al. 2022, Table 4) [11] by imputing the control group peak relative to MS patients and normalizing these values relative to the peak antibody level expected following BNT162b2 booster vaccination [12]. There is currently no long-term antibody waning data on DMTs following vaccination. However, short-term data on the above therapies suggest no difference in waning between DMT patients and a control group or non-MS patients [13]. To predict the trajectory of antibody decline in these cohorts over longer terms, we incorporated longitudinal waning data for anti-N and anti-S IgG antibodies so as to obtain adequate phylogenetic representation of waning of antibodies responsive to six coronaviruses—HCoV-OC43, HCoV-NL63, HCoV-229E, SARS-CoV-1, SARS-CoV-2, and MERS. As in Townsend et al. [14], we utilized a linear model to relate anti-N and anti-S antibody levels—an appropriate model to apply because their decline is strongly correlated [15]. We subjected the antibody waning data to an ancestral and descendant states analysis [14,16] to infer a baseline antibody level and an augmented exponential waning parameter for SARS-CoV-2. Ancestral and descendant states analysis is a well-established technique commonly employed in evolutionary biological research that analyzes the phylogenetic relationships and divergence times between lineages with a model of trait evolution to estimate unknown character states for past or current lineages [17–19]. Extensive analyses have demonstrated that imputed antibody levels supplied by ancestral and descendent states analyses provide robust estimates of antibody waning profiles [14,20] following vaccination against SARS-CoV-2 that have been empirically validated [21,22]. Antibody waning profiles for each cohort were generated based on cohort-specific peak antibody responses. To relate these antibody waning profiles to daily endemic infection probabilities, we fit a logistic infection function as in

Townsend et al [14]. Ancestral and descendent state analysis provided the slope and intercept parameters of the logistic function relating daily antibody level to daily infection probability. These infection probabilities in turn enabled calculation of the cumulative risks of breakthrough infection over time. We then compared these risks across booster schedules [12] with each booster conferring antibody responses as reported in Pitzalis et al. [10].

Results

Annual booster vaccinations over a two-year period provided equivalent protection for individuals without MS and untreated patients with MS, reducing infection risk by more than half (28–29% risk without boosting versus 11% with annual boosting; **Figure 1**). Notably, MS patients receiving interferon therapy experienced an even greater benefit from annual boosters, with their risk of infection dropping to just 6%—a nearly four-fold reduction of the 23% risk without boosting. Patients on dimethyl fumarate, natalizumab, or teriflunomide faced a range of moderately elevated infection risks relative to untreated patients; without boosters, nearly one-third of patients undergoing dimethyl fumarate or natalizumab treatment could become infected over two years. Annual boosting reduced this risk by half, resulting in a 15% risk over the same period. Patients treated with teriflunomide would be more vulnerable to infection relative to untreated MS patients (22% versus 11%) based on their antibody response. However, this prediction regarding teriflunomide is complicated by its unmodeled antiviral properties [23].

Discussion

Our analysis indicates that patients undergoing several MS treatments exhibit risks of infection that are fairly similar to risks for the general population. We showed that frequent

boosting in these populations correlates with better protection. Our analysis of antibody levels and infection probabilities indicates that patients undergoing treatment with interferon, dimethyl fumarate, natalizumab, and teriflunomide would benefit substantially from booster vaccination. MS patients on dimethyl fumarate or natalizumab therapies appear to be at moderately higher infection risk and may warrant additional attentiveness to timely adherence as well as consideration for more intensive vaccination schedules. Teriflunomide-treated patients appeared to face the highest risk; a bi-annual booster schedule might be necessary for patients on teriflunomide to achieve comparable protection against infection.

Our analysis is based solely on the effects of these treatments on antibody levels, and the consequences of those antibody responses to vaccination on infection probability. Some DMTs increase or diminish the antibody response. For instance, interferon increases antibody response to booster vaccination and therefore in our analysis diminishes risk of infection for all booster schedules. On the other hand, some interferon therapies have been linked to increased risk of leukopenia [24–26], which in turn could increase risk of some infections. Nevertheless, studies of the effect of interferon treatment in MS have demonstrated—consistent with our result—that patients are not subject to a generalized increase in risk of viral infection [25].

Conversely, Teriflunomide has been shown to inhibit activated T and B cells [25], and decreases antibody response to booster vaccination [10]. This lower initial antibody response increases risk of infection for all booster schedules. However, studies of teriflunomide have also demonstrated that this therapy has antiviral properties against SARS-CoV-2 [23]. These unmodeled antiviral properties may lead to protection from infection, and therefore justify some concern that our results for teriflunomide may overstate the actual risk of infection at each booster vaccination frequency.

More potently immunosuppressive DMTs exist, including fingolimod, ocrelizumab, and rituximab. These DMTs can reduce the abundance of lymphocytes and alter various B-cell and T-cell traits, thereby impairing the ability to mount an effective immune response post-vaccination. Predicting the effects of these more immunosuppressive therapies poses even greater challenges. The limited data available for our analyses of these treatments ($n < 10$; [10]) indicate that in recently vaccinated MS patients treated with these therapies, the levels of antibodies are typically lower than baseline unvaccinated antibody levels in non-MS populations. Our rates of antibody decline and probabilities of infection are based on those non-MS populations, in whom antibody levels do not decline below this baseline. Consequently, there is no empirical basis enabling our projection of antibody levels subsequent to booster vaccination, nor to associate these low levels of antibody with probabilities of infection. In this context, ascertaining the effect of boosting is highly speculative. However, with such low levels of antibodies, risk of infection is high. Patients on fingolimod and ocrelizumab have been shown to have a reduced response to vaccination against SARS-CoV-2 [10,27,28], and research on cancer patients treated with rituximab has indicated that even monthly boosters would fail to confer substantial protection [29].

Our study uses infection data from fully endemic coronaviruses for long-term predictions, which means it is based on responses to evolving viruses and therefore is appropriate to scenarios involving regularly updated vaccines that target predominant strains. For the same reason, our analysis accounts for waning vaccine efficacy due to antigenic evolution. The infection probabilities we calculated are not based on early trial data, which has limitations for long-term predictions because the immune systems of early trial participants were largely naive to the virus, requiring significant immunological adaptation to develop effective cellular immunity. Our study

does not account for antigenic changes occurring between vaccine production and deployment, which could reduce booster efficacy. Regardless, our findings provide crucial guidance for mitigating SARS-CoV-2 infections in MS patients undergoing various DMTs until extensive longer-term infection data becomes available in this distinct patient population.

Acknowledgements

We thank members of the Townsend and Dornburg lab groups for helpful comments and support.

Data Availability Statement

All data, code, and a detailed readme have been archived on Zenodo and are currently available: https://zenodo.org/doi/10.5281/zenodo.13384814.

Financial Disclosures

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

This work was supported by the National Science Foundation RAPID DEB 2031204 to JPT and AD and the National Science Foundation CCF 1918784 to JPT. The funding sources played no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.

Prior Presentation

This work has not been read or exhibited at a meeting.

References

[1] Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. *Lancet Infect Dis*. 2022;22(7):1002-1010.

[2] Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d'Andrea V, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2023;6(5):e2310650.

[3] Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. *Nat Rev Neurol*. 2012;8(3):143-151.

[4] Mariottini A, Bertozzi A, Marchi L, Di Cristinzi M, Mechi C, Barilaro A, et al. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. *J Neurol*. 2022;269(6):2840-2847.

[5] Muñoz-Jurado A, Escribano BM, Agüera E, Caballero-Villarraso J, Galván A, Túnez I. SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. *J Neurol*. 2022;269(9):4581-4603.

[6] Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. *Neurol Neuroimmunol Neuroinflamm*. 2020;7(4). doi:10.1212/NXI.0000000000000761

[7] Bigaut K, Kremer L, Fabacher T, Lanotte L, Fleury MC, Collongues N, et al. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study. *Neurol Neuroimmunol Neuroinflamm*. 2021;8(5). doi:10.1212/NXI.0000000000001055

[8] Etemadifar M, Nouri H, Pitzalis M, Idda ML, Salari M, Baratian M, et al. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2022;93(9):986-994.

[9] Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. *Immunol Rev*. 2022;310(1):6-26.

[10] Pitzalis M, Idda ML, Lodde V, Loizedda A, Lobina M, Zoledziewska M, et al. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. *Front Immunol*. 2021;12:781843.

[11] Idda ML, Pitzalis M, Lodde V, Loizedda A, Frau J, Lobina M, et al. Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study. *Front Immunol*. 2022;13:946356.

[12] Townsend JP, Hassler HB, Dornburg A. Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting. *J Med Virol*. 2023;95(2):e28461.

[13] Achiron A, Mandel M, Dreyer-Alster S, Harari G, Dolev M, Menascu S, et al. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. *J Neuroimmunol*. 2021;361:577746.

[14] Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. *Lancet Microbe*. 2021;2(12):e666-e675.

[15] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. Published online February 5, 2021.

doi:10.1126/science.abf4063

[16] Townsend JP, Hassler HB, Sah P, Galvani AP, Dornburg A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. *Proc Natl Acad Sci U S A*. 2022;119(31):e2204336119.

[17] Nakagawa S, Freckleton RP. Model averaging, missing data and multiple imputation: a case study for behavioural ecology. *Behav Ecol Sociobiol*. 2011;65(1):103-116.

[18] Thorson JT, van der Bijl W. phylosem: A fast and simple R package for phylogenetic inference and trait imputation using phylogenetic structural equation models. *J Evol Biol*. 2023;36(10):1357-1364.

[19] Goolsby EW, Bruggeman J, Ané C. Rphylopars: fast multivariate phylogenetic comparative methods for missing data and within-species variation. *Methods in Ecology and Evolution*. 2017;8(1):22-27.

[20] Townsend JP, Hassler HB, Dornburg A. Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection. *Clin Infect Dis*. Published online November 26, 2024. doi:10.1093/cid/ciae559

[21] Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, et al. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. *JAMA Netw Open*. 2022;5(1):e2142210.

[22] Bean DJ, Monroe J, Turcinovic J, Moreau Y, Connor JH, Sagar M. Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies. *Clin Infect Dis*. 2022;75(1):e208-e215.

[23] Lang P, Geertsen SS, Lublin AL, Potter MC, Gladysheva T, Gregory JS, et al. evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43. *Biochem Biophys Rep*. 2023;33:101395.

[24] Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. *Ther Adv Neurol Disord*. 2019;12:1756286419836571.

[25] Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. *Nat Rev Neurol*. 2016;12(4):217-233.

[26] Protopapa M, Schmaul S, Schraad M, Pape K, Zipp F, Bittner S, et al. Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis. *Ther Adv Neurol Disord*. 2024;17:17562864241286497.

[27] Capuano R, Altieri M, Conte M, Bisecco A, d'Ambrosio A, Donnarumma G, et al. Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod. *J Neurol*. 2022;269(12):6185-6192.

[28] Orrù V, Serra V, Marongiu M, Lai S, Lodde V, Zoledziewska M, et al. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination. *Front Immunol*. 2024;15:1416464.

[29] Townsend JP, Hassler HB, Emu B, Dornburg A. Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments. *J Natl Cancer Inst*. 2023;115(12):1626-1628.

Figure Legend

Figure 1. Cumulative probabilities of breakthrough infection over a two-year time span for updated BNT162b2 booster doses after primary vaccination, over intervals of one, three, six, or twelve months (colored bands). The analysis compares the general population, untreated MS patients (*n* = 205), and MS patients receiving one of four disease-modifying therapies: interferon (*n* = 135), dimethyl fumarate (*n* = 161), natalizumab (*n* = 74), and teriflunomide (*n* = 56) [10].


Cumulative probabilities of breakthrough infection
0.4
0.0
No MS
28%
11%
3%
1%
Untreated MS
29%
11%
4%
1%
Interferon
23%
6%
1%
Dimethyl fumarate
32%
15%
6%
2%
Natalizumab
32%
15%
6%
2%
Teriflunomide
37%
22%
11%
5%
1%
0
1
2
Years since vaccination
Booster interval (injections)
No boosters
1 year (2×)
6 months (4×)
3 months (8×)
1 month (24×)